ClinicalTrials.gg
CompletedNCT02356562Updated Dec 20, 2017Results posted

A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection

A Phase 2 interventional study of ombitasvir/paritaprevir/ritonavir and dasabuvir and Sofosbuvir in Chronic Hepatitis C Infection, sponsored by AbbVie. Completed. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2017-12-20.

Primary conditionHepatitis C, ChronicRegistry: Hepatitis CReclassifiedWhy we changed it
Registry
Hepatitis C — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hepatitis C, Chronic
Why
  1. The study's listed conditions name Hepatitis C, Chronic, a narrower term within Hepatitis C.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
29
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing ombitasvir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. ombitasvir · Hepatitis C, Chronic.

Enrollment
16th of 19
29 · median 148
Started
2015
with 6 others
Phase 2
7 of 19
none open now
Registered
11th of 19
by date
Lead sponsor
8 of 19
AbbVie

Among the 19 studies testing ombitasvir in Hepatitis C, Chronic, this one is the 16th largest by enrollment, is one of 7 that started in 2015, is one of 7 in phase 2, and was the 11th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 19 studies testing ombitasvir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About ombitasvir

ombitasvir: first FDA approval 2014 (VIEKIRA PAK (COPACKAGED)), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing ombitasvir in Hepatitis C, Chronic as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir (SOF) and ribavirin (RBV) in DAA treatment-experienced adults with Genotype 1 Chronic Hepatitis C Virus infection. This study will contain 2 parts.

Part 1: Approximately 20 participants and at least 10 of the 20 participants previously treated with the combination of ombitasvir/paritaprevir/ritonavir and dasabuvir, with or without RBV, and experienced treatment failure.

Part 2: Approximately 10 participants and all participants previously treated with SOF/ledipasvir and experienced treatment failure.

Read the detailed description

Efficacy, safety, and demographic analyses were performed separately for the 2 study parts using the intent-to-treat (ITT) population, which consists of all enrolled participants who received at least one dose of study drug.

03

Conditions studied

  • Chronic Hepatitis C Infection

Browse trials for

Keywords

  • Hepatitis C
  • Interferon-Free
  • Treatment Experienced
  • Chronic Hepatitis C
  • Hepatitis C Virus
04

In context

Hepatitis C, Chronic Reclassified

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

This study's enrollment of 29 is below the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.

Browse Hepatitis C, Chronic studies →

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Compared within Hepatitis C, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hepatitis C. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of previous direct acting antiviral (DAA) therapy failure; Part 2 only: history of previous direct acting antiviral (DAA) therapy failure and received at least 8 weeks of SOF/ledipasvir; participant must be treatment naïve to all other anti- therapies
  • HCV genotype 1 infection
  • Females must be , of non-child bearing potential or practicing specific forms of

Exclusion criteria

Exclusion Criteria:

  • Positive screen for surface antigen or anti- antibody
  • Discontinuation of the prior DAA treatment for reasons other than virologic failure
  • Confirmed presence of hepatocellular carcinoma
  • Abnormal lab tests
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    3-DAA with or without SOF and RBV

    3-DAA (ombitasvir/paritaprevir/ritonavir once daily \[QD\] and dasabuvir twice daily \[BID\]) with and without sofosbuvir (SOF) QD and with or without ribavirin (RBV) BID for 12 or 24 weeks

    Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir · Drug: Sofosbuvir · Drug: Ribavirin

Interventions

  • Drugombitasvir/paritaprevir/ritonavir and dasabuvir

    Drug pages: Ombitasvir · Paritaprevir · Ritonavir · Dasabuvir

    tablet, ombitasvir coformulated with paritaprevir and ritonavir; tablet, dasabuvir

    Also known as: ABT-450/r/ABT-267, Viekira Pak, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267, dasabuvir also known as ABT-333

  • tablet

    Also known as: Sovaldi

  • tablet

    Also known as: RBV

07

What researchers measure

Primary outcomes

  1. Percentage of Part 1 Participants With Sustained Virologic Response 12 (SVR12) Weeks Posttreatment

    SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug.

    Time frame: 12 weeks after the last dose of active drug

Secondary outcomes

  1. Percentage of Part 2 Participants With Sustained Virologic Response 12 (SVR12) Weeks Post-treatment

    SVR12 was defined as plasma HCV RNA level \<LLOQ 12 weeks after the last dose of study drug

    Time frame: 12 weeks after the last dose of active drug

  2. Percentage of Participants With On-treatment Virologic Failure

    On-treatment virologic failure was defined as confirmed HCV RNA ≥ LLOQ after \< LLOQ during treatment, confirmed increase of \> 1 log (subscript)10(subscript) IU/mL above the lowest post-baseline HCV RNA during treatment, or HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks of treatment.

    Time frame: Up to week 24

  3. Percentage of Participants With Post-Treatment Relapse

    Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after the last dose of study drug among participants completing treatment and with HCV RNA \< LLOQ at the end of treatment.

    Time frame: Within 12 weeks after the last actual dose of active study drug

08

Results

Posted Nov 24, 2017

Participant flow

Efficacy, safety, and demographic analyses were performed separately for the 2 study parts using the intent-to-treat (ITT) population, which consists of all enrolled participants who received at least one dose of study drug.

Participant flow — Overall Study
MilestonePart 1, 3-DAA With SOF With or Without RBVPart 2, 3-DAA With RBV
Started227
Completed206
Not completed21
Withdrew: Withdrawal by subject01
Withdrew: Re-entered treatment in a previous study10
Withdrew: Site closure10

Outcome measures

PrimaryPercentage of Part 1 Participants With Sustained Virologic Response 12 (SVR12) Weeks Posttreatment

SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug.

Time frame:
12 weeks after the last dose of active drug
Reported as:
Number · percentage of participants
Percentage of Part 1 Participants With Sustained Virologic Response 12 (SVR12) Weeks Posttreatment
percentage of participantsPart 1, 3-DAA With SOF With or Without RBV
Percentage of Part 1 Participants With Sustained Virologic Response 12 (SVR12) Weeks Posttreatment95.5 (78.2 to 99.2)
SecondaryPercentage of Part 2 Participants With Sustained Virologic Response 12 (SVR12) Weeks Post-treatment

SVR12 was defined as plasma HCV RNA level \<LLOQ 12 weeks after the last dose of study drug

Time frame:
12 weeks after the last dose of active drug
Reported as:
Number · percentage of participants
Percentage of Part 2 Participants With Sustained Virologic Response 12 (SVR12) Weeks Post-treatment
percentage of participantsPart 2, 3-DAA With RBV
Percentage of Part 2 Participants With Sustained Virologic Response 12 (SVR12) Weeks Post-treatment85.7 (48.7 to 97.4)
SecondaryPercentage of Participants With On-treatment Virologic Failure

On-treatment virologic failure was defined as confirmed HCV RNA ≥ LLOQ after \< LLOQ during treatment, confirmed increase of \> 1 log (subscript)10(subscript) IU/mL above the lowest post-baseline HCV RNA during treatment, or HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks of treatment.

Time frame:
Up to week 24
Reported as:
Number · percentage of participants
Percentage of Participants With On-treatment Virologic Failure
percentage of participantsPart 1, 3-DAA With SOF With or Without RBVPart 2, 3-DAA With RBV
Percentage of Participants With On-treatment Virologic Failure0.0 (0.0 to 14.9)14.3 (2.6 to 51.3)
SecondaryPercentage of Participants With Post-Treatment Relapse

Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after the last dose of study drug among participants completing treatment and with HCV RNA \< LLOQ at the end of treatment.

Time frame:
Within 12 weeks after the last actual dose of active study drug
Reported as:
Number · percentage of participants
Percentage of Participants With Post-Treatment Relapse
percentage of participantsPart 1, 3-DAA With SOF With or Without RBVPart 2, 3-DAA With RBV
Percentage of Participants With Post-Treatment Relapse4.8 (0.8 to 22.7)0.0 (0.0 to 39.0)

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the time of study drug administration until 30 days after the last dose of study drug (up to 28 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1, 3-DAA With SOF With or Without RBV—2/22 (9.1%)20/22 (90.9%)
Part 2, 3-DAA With RBV—0/7 (0%)6/7 (85.7%)
Most frequent serious events
Most frequent serious events
EventPart 1, 3-DAA With SOF With or Without RBVPart 2, 3-DAA With RBV
CELLULITISInfections and infestations1/220/7
PNEUMONIAInfections and infestations1/220/7
Most frequent other events
Showing 10 of 64
Most frequent other events
EventPart 1, 3-DAA With SOF With or Without RBVPart 2, 3-DAA With RBV
FATIGUEGeneral disorders7/223/7
HEADACHENervous system disorders8/221/7
DIARRHOEAGastrointestinal disorders4/221/7
INSOMNIAPsychiatric disorders4/220/7
ANAEMIABlood and lymphatic system disorders0/221/7
GASTROOESOPHAGEAL REFLUX DISEASEGastrointestinal disorders1/221/7
IMPAIRED GASTRIC EMPTYINGGastrointestinal disorders0/221/7
MALAISEGeneral disorders0/221/7
CONJUNCTIVITIS BACTERIALInfections and infestations0/221/7
MUSCLE STRAINInjury, poisoning and procedural complications1/221/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part 1, 3-DAA With SOF With or Without RBVPart 2, 3-DAA With RBVTotal
Mean58.0 ± 6.4165.3 ± 9.60NA ± NA
Sex: Female, Male
Sex: Female, Male(Participants)Part 1, 3-DAA With SOF With or Without RBVPart 2, 3-DAA With RBVTotal
Female718
Male15621
09

Study locations

No study locations are listed for this record.

10

References and documents

Publications

  • King JR, Dutta S, Cohen D, Podsadecki TJ, Ding B, Awni WM, Menon RM. Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir. Antimicrob Agents Chemother. 2015 Nov 23;60(2):855-61. doi: 10.1128/AAC.01913-15. Print 2016 Feb. PubMed 26596948 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2015 to primary completion in Oct 2016, 20 months.

Results were first posted in Nov 2017, 1 year after primary completion.

Of 28 industry-sponsored phase 2 interventional studies under Hepatitis C, Chronic, half reached primary completion within 16 months of starting (the median); a quarter within 10 and three quarters within 28. This study's 20 months is above that.

Counting every sponsor, half of 35 studies reached it within 17 months; a quarter within 11 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2015
First posted
Feb 5, 2015
StartActual
Feb 3, 2015
Primary completionActual
Oct 28, 2016
CompletionActual
Jul 7, 2017
Results first posted
Nov 24, 2017
Last update
Dec 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02356562
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 5, 2015
Start date
Feb 3, 2015
Primary completion
Oct 28, 2016
Completion
Jul 7, 2017
Results posted
Nov 24, 2017
Last update
Dec 20, 2017

Study contacts

Eric Cohen, MD
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ombitasvir · Paritaprevir · Ritonavir · Dasabuvir · Sofosbuvir · Ribavirin

Start the discussion